Christopher Etherton-Beer

Dr. Christopher Etherton-Beer

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2016 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
Amy PageAmy Page
Amy Page
RCRhonda M Clifford
Rhonda M Clifford
KPKathleen Potter
Kathleen Potter
DSDarren Schwartz
Darren Schwartz
CEChristopher Etherton-Beer
Christopher Etherton-Beer

1 June 2015 in The Lancet
Verified
Journal Article
Closed access
Anne-Marie HillAnne-Marie Hill
Anne-Marie Hill
SMSteven Mcphail
Steven Mcphail
NWNicholas Waldron
Nicholas Waldron
CEChristopher Etherton-Beer
Christopher Etherton-Beer
KIKatharine Ingram
Katharine Ingram
THTerry Haines
Terry Haines

4 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KPKathleen Potter
Kathleen Potter
LFLeon Flicker
Leon Flicker
Amy PageAmy Page
Amy Page
CEChristopher Etherton-Beer
Christopher Etherton-Beer
Deprescribing has been proposed as a way to reduce polypharmacy in frail older people. We aimed to reduce the number of medicines consumed by people living in residential aged care facilities (RACF). Secondary objectives were to explore the effect of deprescribing on survival, falls, fractures, hospital admissions, cognitive, physical, and bowel function, quality of life, and sleep. Ninety-five people aged over 65 years living in four RACF in rural mid-west Western Australia were randomised in an open study. The intervention group (n = 47) received a deprescribing intervention, the planned cessation of non-beneficial medicines. The control group (n = 48) received usual care. Participants were monitored for twelve months from randomisation. Primary outcome was change in the mean number of unique regular medicines. All outcomes were assessed at baseline, six, and twelve months. Study participants had a mean age of 84.3±6.9 years and 52% were female. Intervention group participants consumed 9.6±5.0 and control group participants consumed 9.5±3.6 unique regular medicines at baseline. Of the 348 medicines targeted for deprescribing (7.4±3.8 per person, 78% of regular medicines), 207 medicines (4.4±3.4 per person, 59% of targeted medicines) were successfully discontinued. The mean change in number of regular medicines at 12 months was -1.9±4.1 in intervention group participants and +0.1±3.5 in control group participants (estimated difference 2.0±0.9, 95%CI 0.08, 3.8, p = 0.04). Twelve intervention participants and 19 control participants died within 12 months of randomisation (26% versus 40% mortality, p = 0.16, HR 0.60, 95%CI 0.30 to 1.22) There were no significant differences between groups in other secondary outcomes. The main limitations of this study were the open design and small participant numbers. Deprescribing reduced the number of regular medicines consumed by frail older people living in residential care with no significant adverse effects on survival or other clinical outcomes. Australian New Zealand Clinical Trials Registry ACTRN12611000370909

28 March 2011 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
THTerry Haines
Terry Haines
Anne-Marie HillAnne-Marie Hill
Anne-Marie Hill
KHKylie Hill
Kylie Hill
SMSteven Mcphail
Steven Mcphail
DODavid Oliver
David Oliver
CEChristopher Etherton-Beer
Christopher Etherton-Beer
Falls are a leading patient safety incident event in general hospitals and are especially common in older patients.1 Approximately 30% of falls result in injury,2 the consequences of which may cause increased length of stay or risk of institutionalization for the patient,3 and legal complaint with subsequent litigation against the health service.4

20 June 2019 in Medical Journal of Australia
Verified
Journal Article
Open access
PDF file
Amy PageAmy Page
Amy Page
MFMichael O Falster
Michael O Falster
MLMelisa Litchfield
Melisa Litchfield
SPSallie‐Anne Pearson
Sallie‐Anne Pearson
CEChristopher Etherton-Beer
Christopher Etherton-Beer
Objective To estimate the prevalence of polypharmacy among Australians aged 70 years or more, 2006–2017. Design, setting and participants Analysis of a random 10% sample of Pharmaceutical Benefits...

31 January 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
OAOsvaldo P. Almeida
Osvaldo P. Almeida
GGGriselda J. Garrido
Griselda J. Garrido
CEChristopher Etherton-Beer
Christopher Etherton-Beer
NLNicola T. Lautenschlager
Nicola T. Lautenschlager
LALeonard Arnolda
Leonard Arnolda
LFLeon Flicker
Leon Flicker
It is unclear whether the cognitive dysfunctionassociated with heart failure (HF) is due to HF or comorbid conditions such as ischaemic heart disease (IHD). This study aimed to determine whether, compared with controls with and without IHD, adults with systolic HF show evidence of cognitive impairment and cerebral grey matter (GM) loss. Cross-sectional study of 35 participants with HF, 56 with IHD, and 64 controls without either HF or IHD. Subjects were older than 45 years and free of overt cognitive impairment. We acquired magnetic resonance images and used SPM8 to determine regional differences in cerebral GM volume. Participants with HF had lower scores than controls without IHD on immediate memory, long delay recall and digit coding, whereas those with IHD had lower long delay recall scores than controls without IHD. Compared with controls without IHD, participants with HF showed evidence of GM loss in the left cingulate, the right inferior frontal gyrus, the left middle and superior frontal gyri, the right middle temporal lobe, the right and left anterior cingulate, the right middle frontal gyrus, the inferior and pre-central frontal gyri, the right caudate, and occipital-parietal regions involving the left precuneus. The loss of GM followed a similar, less extensive, pattern when we compared participants with HF and IHD. Adults with HF have worse immediate and long-term memory and psychomotor speed than controls without IHD. Heart failure is associated with changes in brain regions that are important for demanding cognitive and emotional processing.